Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

23.86 +0.83 (+3.60%)
Streaming Delayed Price Updated: 11:08 AM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 Next >
News headline image
Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Appoints Carlos Santos as Chief Financial Officer
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Host Investor Conference Call on Second Quarter 2025 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Reports First Quarter 2025 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Appoints Alan Bash as President of CARVYKTI®
Newly created position to lead efforts focused on continued growth and sales 
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
New 31,000 square-foot facility will enhance Legend’s leading cell therapy portfolio and expand Legend’s R&D capabilities as a global cell therapy leader 
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
From Legend Biotech USA Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.